Covalent p300 inhibitor compounds
Novel covalent inhibitor compounds targeting p300's acetyltransferase activity and bromodomain provide a therapeutic solution for diseases like cancers and neurodegenerative disorders by selectively inhibiting p300 activity.
WO2026128761A1PCT designated stage Publication Date: 2026-06-18NEXO THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- NEXO THERAPEUTICS INC
- Filing Date
- 2025-12-11
- Publication Date
- 2026-06-18
Smart Images
Figure US2025059286_18062026_PF_FP_ABST
Abstract
This disclosure provides compounds of Formula (I): or pharmaceutically acceptable salts thereof and methods of using such compounds (e.g., as p300 inhibitors), wherein the compounds have an electrophilic sulfur(VI) exchange reactive group. Also provided are pharmaceutical compositions including the compounds, and methods for using such compounds and compositions in research or as therapeutics (e.g., anticancer therapeutics).
Need to check novelty before this filing date? Find Prior Art